AMPK–SQSTM1 Double Feedback Drives Dual Antioxidant Pathway Activation Under Metabolic Stress

Study Background and Research Question

Within the tumor microenvironment, chronic inflammation, nutrient deprivation, and the buildup of reactive oxygen species (ROS) collectively impose metabolic and oxidative stresses on cells. Tumor cells, particularly in non-small cell lung cancer (NSCLC), often acquire mutations in STK11/LKB1 and KEAP1, affecting central regulators of metabolic and antioxidant responses. The AMP-activated protein kinase (AMPK) pathway, activated by STK11/LKB1, helps cells adapt to energy stress, while the KEAP1–NFE2L2/NRF2 axis controls the antioxidant defense. However, the molecular mechanisms integrating metabolic and redox stress responses, and the impact of co-occurring mutations, have remained poorly defined. The authors of the reference study set out to dissect how metabolic stress coordinates the crosstalk between AMPK and NFE2L2/NRF2 pathways, focusing on the regulatory role of SQSTM1/p62.

Key Innovation from the Reference Study

The central innovation of this research is the discovery of a double-positive feedback loop between AMPK and SQSTM1/p62. This feedback leads to dual activation of both AMPK and NFE2L2/NRF2, thereby synergizing antioxidant defenses under metabolic stress. The study reveals that phosphorylation and increased expression of SQSTM1 are both critical drivers and outputs of this loop, integrating metabolic and oxidative signals. Notably, this mechanism provides a molecular rationale for why co-mutations in STK11/LKB1 and KEAP1 are prevalent in NSCLC, as these mutations converge on pathways enhancing cell survival under stress.

Methods and Experimental Design Insights

The experimental strategy combined cell biology, genetic manipulation, biochemical assays, and imaging in cultured cells and animal models. The authors used cell lines with defined mutations in STK11/LKB1 and KEAP1, and subjected them to metabolic stress via glucose deprivation. Key protein levels and phosphorylation states were assessed by immunoblotting, while functional interactions between AMPK, SQSTM1, KEAP1, and NFE2L2/NRF2 were evaluated by immunoprecipitation and co-localization studies. The team further dissected the role of lysosomal function (using V-ATPase inhibitors) and ROS signaling in modulating these pathways. Site-directed mutagenesis of SQSTM1 was used to identify the importance of specific phosphorylation sites (S24 and S226) for pathway activation. Pharmacological tools, including TAK1 inhibitors, aided in characterizing the upstream signals leading to SQSTM1 phosphorylation. Tumor growth assays and antioxidant response measurements provided physiological relevance to the molecular findings.

Core Findings and Why They Matter

The study presents several interlinked discoveries:

• Metabolic stress upregulates and phosphorylates SQSTM1/p62, which is essential for activating both AMPK and NFE2L2/NRF2. This dual activation bolsters antioxidant defenses and promotes tumor growth under stress conditions.
• Feedback loop architecture: SQSTM1 induces macroautophagic degradation of KEAP1 (relieving NFE2L2/NRF2 inhibition) and facilitates assembly of the AXIN–STK11–AMPK complex on lysosomal membranes (supporting AMPK activation). Conversely, AMPK activity is required for the stress-induced expression and phosphorylation of SQSTM1, establishing reciprocal reinforcement.
• Regulatory mechanisms: SQSTM1 expression is upregulated by PP2A-dependent dephosphorylation of TFEB/TFE3, which is triggered by lysosomal deacidification from low glucose and AMPK-dependent proton reduction. SQSTM1 phosphorylation is mediated by MAP3K7/TAK1, itself activated by ROS and pH-dependent lysosomal Ca²⁺ release.
• Phosphorylation dependence: Phosphorylation of SQSTM1 at S24 and S226 is critical for the dual activation of AMPK and NFE2L2/NRF2; mutation at these sites impairs the antioxidant and metabolic adaptation response.
• Metabolic context: The feedback loop is sensitive to pH changes; lactic acid-derived protons can suppress the effects of metabolic stress, highlighting a metabolic checkpoint in the stress response.

These findings provide a mechanistic explanation for how cancer cells integrate metabolic and oxidative stress signals, and why mutations that affect both AMPK and NFE2L2/NRF2 pathways are selected during tumor evolution. This expands our understanding of tumor adaptability and opens new avenues for therapeutic targeting of the metabolic-redox axis in cancer.

Comparison with Existing Internal Articles

Several internal resources have examined the use of TAK1 inhibitors, such as (5Z)-7-Oxozeaenol in inflammation research and advanced cellular stress models. These articles underscore the selectivity of (5Z)-7-Oxozeaenol as a TAK1 inhibitor and its utility in dissecting NF-κB and JNK/p38 MAPK signaling. The current reference study builds upon this by highlighting TAK1's role in phosphorylating SQSTM1 during metabolic stress, linking TAK1 inhibition to the broader regulation of metabolic and antioxidant pathways. Notably, the workflow optimization resource (see here) provides actionable protocols for using TAK1 inhibitors in metabolic assays, which aligns with the mechanistic insights from the present study. Thus, the new findings bridge inflammatory signaling and metabolic adaptation, offering a more integrated view of TAK1's role.

Limitations and Transferability

While the feedback mechanism was robustly demonstrated in cell lines and supported by animal data, the complexity of human tumors may introduce additional regulatory factors not captured in these models. The study primarily focused on NSCLC contexts with STK11 and KEAP1 mutations, so transferability to other cancer types or inflammatory conditions should be experimentally validated. Additionally, although TAK1’s involvement in SQSTM1 phosphorylation was substantiated, the potential for compensatory kinases or context-dependent modulation remains to be fully characterized.

Protocol Parameters

• TAK1 inhibition for SQSTM1 phosphorylation studies: Literature suggests using potent TAK1 inhibitors at 500 nM concentration with up to 17.5 hours incubation in cell culture systems, as supported by product documentation.
• Metabolic stress induction: Glucose deprivation protocols typically involve culturing cells in glucose-free medium for 12–24 hours to elicit robust AMPK and NFE2L2/NRF2 responses.
• Lysosomal pH modulation: Application of V-ATPase inhibitors such as bafilomycin A1 or concanamycin A can be used at 50–100 nM for 2–6 hours to study the impact of lysosomal deacidification on stress pathways.
• Site-directed mutagenesis: To probe the role of SQSTM1 phosphorylation, S24A and S226A mutants can be expressed in SQSTM1-deficient backgrounds for functional comparison with wild-type controls.
• ROS modulation: Use of N-acetylcysteine (NAC) as a ROS scavenger (1–5 mM, 1–4 hours) can help delineate ROS-dependent signaling contributions.

Research Support Resources

For researchers seeking to experimentally dissect TAK1’s role in SQSTM1 phosphorylation and its impact on AMPK–NFE2L2/NRF2 crosstalk, (5Z)-7-Oxozeaenol (SKU B7443) is a validated, selective TAK1 inhibitor suitable for cell culture and animal model workflows. Detailed usage protocols and storage guidelines are provided in the product documentation. Integrating such inhibitors can support advanced studies into metabolic and inflammatory signaling, as highlighted by the reference study and internal comparative analyses.